CMCelina Borges Migliavaca

Celina Borges Migliavaca

*This is an algorithmically generated author record based on publicly available information.

Celina Borges Migliavaca has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In response to “Caveats for systematic reviews of prevalence studies”

    by Julian Pt Higgins, Celina Borges Migliavaca, Diana Buitrago-Garcia, Zachary Munn

  • Systematic reviews of prevalence: challenges and future steps

    by Julian Pt Higgins, Celina Borges Migliavaca, Diana Buitrago-Garcia, Zachary Munn


  • Diverse structures and methods of national health technology assessment organizations: A scoping review

    by Celina Borges Migliavaca, Verônica Colpani, Miriam Allein Zago Marcolino, Maicon Falavigna, Carisi Anne Polanczyk


  • Open Access

    Brazilian Database: elaboração de base bibliográfica de estudos brasileiros na área de ATS

    by Nayê Balzan Schneider, Gilson Pires Dorneles, Bruna Marmett, Felipe Borges Migliavaca, Jaqueline Angela Casaes e Silva, Celina Borges Migliavaca, Maicon Falavigna

    Introdução: As bases de dados bibliográficas são essenciais para obter informações de forma rápida e padronizada1. Atualmente, a busca por informações brasileiras relacionadas à Avaliação de Tecnologias de Saúde (ATS) é desafiadora, e geralmente, é realizada pelo acesso individual das publicações em periódicos online ou sites institucionais. Esta fragmentação das informações dificulta a obtenção de evidências locais, aumentando o tempo necessário e a complexidade para localizar informações, além de impactar negativamente na reprodutibilidade de buscas. Durante a última década, bases de informações de ATS foram elaboradas em diferentes cenários2,3. Nesse contexto, a criação de uma base bibliográfica para estudos brasileiros na área de ATS configura-se como uma ferramenta estratégica para facilitar a disseminação e o acesso à informação. Objetivo: Apresentar a base bibliográfica de estudos de ATS nacionais, a Brazilian Database. Material e Método: Para o desenvolvimento da base bibliográfica, primeiramente foram identificadas revistas científicas e anais de congressos com produções brasileiras na área de ATS. Após, foi realizada a extração manual das seguintes informações de cada documento identificado: título, autores, ano de publicação, resumo, palavras-chave, link para arquivo original e DOI. O título, resumo e palavras-chave, extraídos na língua original, foram traduzidos para o inglês ou português por meio de inteligência artificial. Foram criadas variáveis adicionais para facilitar o gerenciamento dos dados: ID (identificador único da referência), fonte (de onde a referência foi extraída), tipo de documento (resumo de congresso, artigo completo, dossiê, relatório de recomendação, protocolos, diretrizes e PCDTs), e referência para citação (formatada no estilo Vancouver). O desenvolvimento do sítio eletrônico foi realizado em WordPress e hospedado no domínio https://data.com. Atualmente, o uso da base bibliográfica é gratuito para fins não comerciais. Resultados: Foram identificadas como fontes prioritárias de documentos, os sítios eletrônicos da ISPOR, CONITEC, ANS e REBRATS, além das revistas brasileiras Jornal de assistência farmacêutica e farmacoeconomia (JAFF) e Jornal brasileiro de economia da saúde (JBES). A base inclui os registros destas fontes até a data de 30 de junho de 2024, incluindo 591 artigos do JAFF, 535 artigos do JBES, 871 documentos da CONITEC, e 101 resumos de congresso da REBRATS; atualmente, 1751 documentos da ISPOR e 750 da ANS estão em processo de catalogação. A busca por conteúdo pode ser conduzida de forma sistemática a partir de termos de interesse e operadores booleanos. A atualização da base, com inserção de novos documentos, será realizada mensalmente. Conclusões: A Brazilian Database permite que pesquisadores, profissionais da saúde e gestores encontrem rapidamente estudos relevantes para suas necessidades. Além disso, promove a disseminação da pesquisa nacional ao permitir acesso bilíngue e centralizado da produção científica brasileira na área.

  • Open Access

    PD192 Criteria For Decision-Making In Health Economic Evaluations: An Analysis Of Global Practices

    by Celina Borges Migliavaca, Verônica Colpani, Miriam Allein Zago Marcolino, Maicon Falavigna, Carisi Anne Polanczyk

    Introduction: Economic criteria have become critical for health technology assessment (HTA) due to the rising costs of health technologies. The use of explicit, predefined criteria for economic evaluations enhances the transparency, objectivity, and predictability of the process. We aimed to identify which organizations worldwide integrate explicit and predefined criteria into their health economic analyses during HTA.Methods: We conducted a scoping review to identify organizations responsible for HTA processes at the national level in any country. The identification of eligible organizations was carried out by reviewing members of the EUnetHTA, HTAsiaLink, INAHTA, and RedETSA networks as well as organizations evaluated in reviews with a similar scope. For each eligible organization, information was extracted on the inclusion of economic factors during decision-making and the existence of predefined criteria for judging the results of economic evaluations.Results: Sixty-nine organizations from 56 countries were identified, of which 66 (96%) considered economic factors for HTA. Fifty-two (79%) organizations conducted cost-effectiveness analyses, 42 (64%) assessed budget impact, and one focused solely on total technology costs. Thirty-four organizations (51%) declare not having criteria for economic evaluation, whereas 14 (21%) from 12 countries had explicit criteria. There were no data found for 18 organizations (27%). Among the organizations with explicit criteria, 11 (17%) applied willingness-to-pay thresholds in cost-effectiveness evaluations and five (8%) applied criteria related to budget impact for decision-making, such as a maximum percentage of budget impact.Conclusions: Although most organizations consider economic factors for HTA, many do not have explicit, predefined criteria for decision-making. Among those that presented such criteria, willingness-to-pay thresholds for cost-effectiveness analyses were the most common. The findings of this study also help to identify complementary factors that can be considered to promote greater systematization and transparency in the decision-making process.

  • Open Access

    PD60 The Importance Of Systematic Reviews Addressing Questions Of Prevalence In Health Technology Assessment

    by Celina Borges Migliavaca, Timothy Hugh Barker, Cinara Stein, Verônica Colpani, Zachary Munn, Maicon Falavigna

    Introduction: The use of systematic reviews (SRs) of interventions is commonplace in health technology assessment (HTA). However, SRs synthesizing other data types, such as prevalence, are rarely used. These SRs may complement the HTA process by gathering complementary evidence essential for developing trustworthy recommendations. We aimed to discuss the importance and application of SRs of prevalence in the context of HTA.Methods: A methodological working group, the Prevalence Estimates Reviews – Systematic Review Methodology Group (PERSyst), was created to provide guidance on how to improve the development of SRs and meta-analyses of prevalence. As part of the group’s work, a guide for HTA developers regarding the value of SRs of prevalence was developed.Results: There are many benefits to including SRs of prevalence in the process of HTA. These include providing data for estimating burden of disease; helping to set priorities regarding technology assessment; informing the absolute impact on health outcomes from association measures (e.g., relative risk) reported in clinical studies; and providing data for estimating resource requirements for and feasibility of implementing health technologies under consideration. Within the GRADE framework, prevalence estimates are necessary to assess the quality of diagnostic test accuracy evidence and to support decision-making using the Evidence to Decision framework.Conclusions: Although not commonly used, SRs of prevalence are an important tool in the process of HTA. There is a need for standardization of methodologies and guidance on how to use these reviews in the HTA process.

  • Open Access

    PP71 Organizations Responsible For The Evaluation Of Health Technologies Globally: A Scoping Review

    by Celina Borges MigliavacaCelina Borges Migliavaca, Verônica Colpani, Miriam Allein Zago Marcolino, Maicon Falavigna, Carisi Anne Polanczyk

    Introduction: The process of health technology assessment (HTA) is a valuable tool for the pursuit of equitable and sustainable healthcare systems. Various countries have established organizations dedicated to conducting HTAs, adapting such institutions to local healthcare ecosystems. The aim of this study was to evaluate the structure, methods, and processes of organizations responsible for national-level HTAs globally.Methods: A scoping review was conducted assessing organizations responsible for conducting HTAs for national-level decision-making in any country. Identification of eligible organizations was performed through a review of member organizations of INAHTA, EUnetHTA, RedETSA, and HTAsiaLink networks, as well as organizations evaluated in reviews with a similar scope. For each organization, the following data were searched: country, year of foundation, organizational nature, role in decision-making, funding, technologies assessed, criteria considered for decision-making (such as efficacy and safety, costs, impact on equity, among others), type of economic evaluation, and patient involvement.Results: We identified 69 organizations, from 56 countries, mainly European (n=39; 56%). Fifty-three (77%) are government-affiliated; most (n=51; 74%) have a consultative role. Public funding is the main funding, and 12 (17%) organizations charge fees for conducting HTA. Technologies assessed include drugs (n=61; 88%), devices (n=47; 68%), and procedures (n=33; 48%). HTA is usually initiated upon request from the manufacturer (n=45; 65%). Patient involvement is not clearly described in 32 organizations (46%); in 29 organizations (42%), the role of patients is to provide information that is considered during decision-making.Conclusions: Among the evaluated organizations, it is observed that the majority are government-affiliated, have public funding, and play a consultative role. The results of this study serve as an important reference for the development and improvement of organizations responsible for conducting HTAs.

  • Open Access

    Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence

    by Rodolfo Delfini Cançado, Fernando Ferreira Costa, Clarisse Lobo, Celina Borges Migliavaca, Maicon Falavigna, Homero C. R. Souza Filho, Carolina Tosin Bueno, Ana Cristina Silva-Pinto

    Sickle cell disease (SCD) is a group of hereditary chronic diseases with a substantial impact on quality of life and morbimortality. In Brazil, it is 1 of the most common hereditary diseases; however, there are sparse epidemiological data for the country. Using data from death certificates, we aimed to estimate the median age at death, years of life lost because of SCD, and the median survival. From 2015 to 2019, we identified 3320 records of deaths of individuals with SCD, from a total of 6 553 132 death records. Among individuals with SCD, the median age at death was 37 years less than that of the general population (SCD: aged 32.0 years at death, interquartile range [IQR], 19.0-46.0; general population: aged 69.0 years at death; IQR, 53.0-81.0). Results were consistent when stratified by sex or race. Over the 5 years evaluated, crude death rates varied from 0.30 to 0.34 per 100 000 inhabitants (mean 0.32 per 100 000 inhabitants). We estimated a prevalence of 60 017 individuals living with SCD (29.02 cases per 100 000) and an average incidence of 1362 cases yearly. The median estimated survival was 40 years for individuals with SCD and 80 years for the general population. SCD was associated with an increased risk of mortality in most age ranges. Among individuals with SCD aged between 1 and 9 years and between 10 and 39 years, the risk of death was 32 and 13 times higher, respectively. The most common causes of death were sepsis and respiratory failure. These results highlight the burden of SCD in Brazil and the necessity of improved care for this population.


  • Open Access

    Innovative mechanisms of pre-marketing authorization access for rare diseases in Brazil: a case study of pabinafusp-alfa for mucopolysaccharidosis type II

    by Maicon Falavigna, Celina Migliavaca, Elio Tanaka, Marcos Santos

    Patients with rare diseases frequently face unmet medical needs due to the high costs, lengthy development times, and slow approval processes for new treatments. This case study discusses innovative access alternatives for rare diseases in Brazil, focusing on early access to pabinafusp-alfa for mucopolysaccharidosis type II (MPS-II), a rare genetic lysosomal storage disease characterized by a deficiency of the enzyme iduronate-2-sulfatase. From September 2018 to March 2023, 20 Brazilian MPS-II patients received pabinafusp-alfa through a clinical research protocol. This enzyme replacement therapy (ERT) crosses the blood-brain barrier to address central nervous system manifestations unmet by existing treatments. Patients’ participation in the clinical study resulted in an estimated BRL 65 million in cost savings for the public healthcare system compared to conventional ERT with idursulfase-alfa and potentially better clinical outcomes. The case study underscores the importance of innovative mechanisms in addressing patients’ medical needs. Early access alternatives include: a) clinical study access, with execution/development aligned with healthcare managers and linked to future access strategies; b) regulatory-level risk-sharing, considering effectiveness uncertainties and the possibility of market withdrawal and/or reimbursement in case of negative results; and c) drug pre-delivery, with payment contingent on positive phase III clinical study outcomes. Although public-private partnerships in clinical research are underused, they could benefit all stakeholders by accelerating drug development, facilitating early patient access to innovative medicines, and generating healthcare system savings, particularly for rare diseases.

  • Internal Ventricular Cerebrospinal Fluid Shunt for Adult Hydrocephalus: A Systematic Review and Meta-Analysis of the Infection Rate

    by Rado Malalatiana Ramasy Razafindratovo, Celina Borges Migliavaca, Sylvie Chevret, Charles Champeaux-Depond

    BACKGROUND: Hydrocephalus is a common neurological condition that usually requires internal ventricular cerebrospinal fluid shunt (IVCSFS). The reported infection rate (IR) varies greatly from below 1% up to over 50%, but no meta-analysis to assess the overall IR has ever been performed. OBJECTIVE: To determine the IVCSFS overall IR in the adult population and search for associated factors. METHODS: Six databases were searched from January 1990 to July 2022. Only original articles reporting on adult IVCSFS IR were included. Random-effects meta-analysis with generalized linear mixed model method and logit transformation was used to assess the overall IR. RESULTS: Of 1703 identified articles, 44 were selected, reporting on 57 259 patients who had IVCSFS implantation and 2546 infections. The pooled IR value and its 95% CI were 4.75%, 95% CI (3.8 to 5.92). Ninety-five percent prediction interval ranged from 1.19% to 17.1%. The patients who had IVCSFS after intracranial hemorrhage showed a higher IR (7.65%, 95% CI [5.82 to 10], P-value = .002). A meta-regression by year of publication found a decreasing IR (−0.031, 95% CI [−0.06 to 0.003], P-value = .032) over the past 32 years. CONCLUSION: IVCSF is a procedure that every neurosurgeon should be well trained to perform. However, the complication rate remains high, with an estimated overall IR of 4.75%. The IR is especially elevated for hydrocephalic patients who require IVCSFS after intracranial hemorrhage. However, decades of surgical advances may have succeeded in reducing IR over the past 32 years.